Who are Albendazole on Day 1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paclitaxel (albumin-bound), ''albendazole'' and ''ivermectin'', Paclitaxel injection, albendazole and praziquantel, Docetaxel or albumin paclitaxel, Placebo plus Docetaxel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/albendazole-on-day-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Albendazole on Day 1 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Albendazole on Day 1 (Albendazole on Day 1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Benzimidazole anthelmintic. Area: Infectious Disease / Parasitology.

phase 3 Benzimidazole anthelmintic β-tubulin Infectious Disease / Parasitology Small molecule Live · refreshed every 30 min

Target snapshot

Albendazole on Day 1 (Albendazole on Day 1) — Lihir Medical Centre. Albendazole inhibits microtubule polymerization in parasitic worms by binding to β-tubulin, disrupting their cytoskeletal structure and causing paralysis and death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Albendazole on Day 1 TARGET	Albendazole on Day 1	Lihir Medical Centre	phase 3	Benzimidazole anthelmintic	β-tubulin
Paclitaxel (albumin-bound)	Paclitaxel (albumin-bound)	Dai, Guanghai	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)
''albendazole'' and ''ivermectin''	''albendazole'' and ''ivermectin''	Centre d'Appui à la lutte contre la Maladie	marketed	Antihelmintic/Antiparasitic agents	β-tubulin (albendazole); glutamate-gated chloride channels (ivermectin)
Paclitaxel injection	Paclitaxel injection	Guangzhou Double Bioproducts Co., Ltd	marketed	Taxane; microtubule stabilizer	β-tubulin
albendazole and praziquantel	albendazole and praziquantel	R-Evolution Worldwide S.r.l. Impresa Sociale	marketed	Anthelmintic combination	β-tubulin (albendazole); calcium channels (praziquantel)
Docetaxel or albumin paclitaxel	Docetaxel or albumin paclitaxel	Shandong Cancer Hospital and Institute	marketed	Taxane; microtubule-stabilizing chemotherapy agent	β-tubulin (microtubule)
Placebo plus Docetaxel	Placebo plus Docetaxel	Infinity Pharmaceuticals, Inc.	marketed	Taxane (microtubule stabilizer)	Microtubules (β-tubulin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Benzimidazole anthelmintic class)

Lihir Medical Centre · 1 drug in this class
London School of Hygiene and Tropical Medicine · 1 drug in this class
Universidad Nacional de Salta · 1 drug in this class
University of Kelaniya · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Albendazole on Day 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/albendazole-on-day-1. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab